skip to Main Content
April 30, 2020 1:00 - 2:00 PM ET

Understanding Shifts from Medicare Part B to D in Autoimmune Treatment

  • This page as PDF


Avalere experts examined evolving stakeholder-specific considerations for reshaping how patients with autoimmune conditions receive care during and after the COVID-19 pandemic.

Treatment for autoimmune conditions continue to see significant Medicare program changes during the COVID-19 pandemic. Current shifts and flexibilities attempt to mitigate the interruptions in care through providing solutions that balance safety and access to necessary treatment. However, these health system disruptions resulting from COVID-19 are significantly reshaping how patients receive care. Unanticipated changes in utilization, such as a large shift from provider-administered to self-administered drugs, will impact coverage, utilization management, and health plan costs. Additionally, there are clinical challenges that must be closely considered by patients and physicians for transition to a new therapy. All healthcare stakeholders will need to understand the immediate and future effects of these changes.

Key topics included:

  • Policy shifts during COVID-19
  • Current status of Medicare Part B and D
  • Provider and patient access and impact
  • Future state of the Medicare B and D benefits
  • Coverage and cost implications


Sarah Butler , Head, Client Solutions, Marketing & Operations

Sarah Butler specializes in evidence-based medicine, value-based contracting, and strategy development.

Kayla Amodeo , Associate Principal, Policy

Kayla Amodeo serves as a key subject-matter expert on Medicare Part B, drug pricing, and value assessment policy-related issues impacting the pharmaceutical industry, physicians, the federal government, and other stakeholders.

John E. Linnehan , Practice Director, Health Economics & Advanced Analytics

John E. Linnehan leads a team of consultants, strategists, and data scientists focused on driving healthcare improvement through value demonstration, stakeholder engagement, predictive and applied analytics, and data innovations.

Michael Schneider , Principal

Mike Schneider is an experienced health care executive with over 20 years of experience in pharmaceutical manufacturer, pharmacy benefit manager, and payer side of health care.

From beginning to end, our team synergy
produces measurable results. Let's work together.

Sign up to receive more insights about Value-Based Care
Please enter your email address to be notified when new Value-Based Care insights are published.

Back To Top